Takeda launches late-stage trial program for Type 2 diabetes drug

First phase 3 trial of TAK-475 to enroll 450 patients

OSAKA, Japan — Takeda Pharmaceuticals has started a late-stage clinical trial program for a drug to treat Type 2 diabetes, the drug maker said.

Takeda announced the start of the phase 3 trial of TAK-875 in the United States, Latin America and Europe. Previous studies have indicated that the drug, which belongs to a class known as GPR40 agonists, lowers glucose in patients' blood by stimulating the secretion of glucose-dependent insulin in the pancreas. The first phase-3 trial in the program will enroll about 450 patients in the United States, Latin America and Europe.

"Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new Type 2 diabetes treatment option for patients and healthcare professionals," Takeda Global Research and Development Center VP clinical science Thomas Strack said. "An outcome of our robust focus on diabetes over many years, TAK-875 was discovered by Takeda based on our GPRC research and is the first GPR40 agonist to reach late-stage clinical development."

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.